Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 217fludarabine phosphate 120Rituximab 108Filgrastim 100Peripheral Blood Stem Cell Transplantation 86Etoposide 83fludarabine 80Busulfan 80Radiotherapy 76Tacrolimus 73Methotrexate 73Melphalan 71Mycophenolic Acid 70Cytarabine 65Antilymphocyte Serum 61Whole-Body Irradiation 56Cyclosporine 54Vincristine 49Prednisone 42Doxorubicin 41Methylprednisolone 34Granulocyte Colony-Stimulating Factor 34Dexamethasone 30Cord Blood Stem Cell Transplantation 29sargramostim 27Alemtuzumab 26Stem Cell Transplantation 24Carmustine 24Thiotepa 23thymoglobulin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Fenofibrate × Other hematologic neoplasm × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡